Table 2.

Summary of Toxicity ≥Grade 3 with RT-ICI combinations in NSCLC.

Study Design	Follow-Up in Months, Median, Range	Toxicity ≥ Grade 3 %, Weighted Median	Most Common irAEs
AntiPD1/antiPD-L1 + SABR	14.0 (2,9–33)	14,5%	Pneumonitis, asthenia, breakthrough pain, colitis, neurological and hepatic toxicity
Anti CTLA4 + SABR	20.0 (2–38)	26,0%	Pneumonitis, fatigue, liver enzymes increase, colitis and neurological
AntiPD1/AntiPD-L1 alone	11.0 (7–14,5)	10,8%	Pneumonia, increased aspartate aminotransferase, skin reactions, pneumonitis, neutropenia, anemia, thrombocytopenia, diarrhea

IT = immunotherapy; RT = radiotherapy; irAEs = immune-related adverse events.